Anti-TNF Therapies Suppress Adipose Tissue Inflammation in Crohn's Disease
Boronat-Toscano, Albert (Universitat Rovira i Virgili)
Monfort-Ferré, Diandra (Universitat Rovira i Virgili)
Menacho, Margarita (Hospital Universitari Joan XXIII de Tarragona)
Caro, Aleidis (Hospital Universitari Joan XXIII de Tarragona)
Bosch Príncep, Ramon (Hospital de Tortosa Verge de la Cinta)
Espina, Beatriz (Hospital Universitari Joan XXIII de Tarragona)
Algaba, Ferran (Universitat Rovira i Virgili)
Saera-Vila, Alfonso (Sequentia Biotech (Barcelona))
Moliné, Alicia (Hospital Universitari Joan XXIII de Tarragona)
Marti-Gallostra, Marc (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Espin-Basany, Eloy (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Millan, Mónica (Hospital Universitari i Politècnic La Fe (València))
Serena, Carolina (Universitat Rovira i Virgili)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Anti-TNF biologics have been shown to markedly improve the quality of life for patients with Crohn's disease (CD), yet one-third of patients fail to benefit from this treatment. Patients with CD develop a characteristic wrapping of visceral adipose tissue (VAT) in the inflamed intestinal area, termed creeping fat, and it is known that adipose tissue expansion influences the efficacy of anti-TNF drugs. We questioned whether anti-TNF therapies impact the creeping fat in CD, which might affect the outcome of the disease. Adipose tissue biopsies were obtained from a cohort of 14 patients with CD that received anti-TNF drugs and from 29 non-anti-TNF-treated patients (control group) matched by sex, age, and body mass index undergoing surgical interventions for symptomatic complications. We found that anti-TNF therapies restored adipose tissue morphology and suppressed immune cell infiltration in the creeping fat. Additionally, anti-TNF treatments appeared to markedly improve the pro-inflammatory phenotype of adipose-tissue macrophages and adipose-tissue-derived stem cells. Our study provides evidence that anti-TNF medications influence immune cells and progenitor cells in the creeping of patients with CD, suppressing inflammation. We propose that perilesional VAT should be considered when administering anti-TNF therapy in patients with CD.
Ajuts:	Instituto de Salud Carlos III PI18/00037 Ministerio de Economía y Competitividad RYC2013-13186 Agència de Gestió d'Ajuts Universitaris i de Recerca 2022-B00577
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adipose tissue ; Infliximab ; Adalimumab ; TNF ; Creeping fat
Publicat a:	International journal of molecular sciences, Vol. 23 (september 2022) , ISSN 1422-0067

DOI: 10.3390/ijms231911170
PMID: 36232469

15 p, 2.5 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats